<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>AIM: The incretin hormones, glucagon-like <z:chebi fb="7" ids="16670">peptide</z:chebi>-1 (GLP-1) and <z:chebi fb="105" ids="17234">glucose</z:chebi>-dependent insulinotropic <z:chebi fb="1" ids="15841">polypeptide</z:chebi> (GIP) and cholecystokinin (CCK) are gastrointestinal <z:chebi fb="7" ids="16670">peptides</z:chebi> with important physiological effects </plain></SENT>
<SENT sid="1" pm="."><plain>However, rapid enzymatic degradation results in short-lived biological actions </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS: This study has examined metabolic actions of exendin-4, GIP[mPEG] and a novel CCK-8 analogue, (pGlu<z:chebi fb="0" ids="32668">-Gln</z:chebi>)-CCK-8 as enzymatically stable forms of GLP-1, GIP and CCK, respectively </plain></SENT>
<SENT sid="3" pm="."><plain>RESULTS: <z:hpo ids='HP_0000001'>All</z:hpo> <z:chebi fb="7" ids="16670">peptides</z:chebi> significantly (p &lt; 0.01-p &lt; 0.001) stimulated insulin secretion from BRIN BD11 cells, and <z:hpo ids='HP_0011009'>acute</z:hpo> in vivo experiments confirmed prominent antihyperglycaemic and insulinotropic responses to GLP-1 or GIP receptor activation in <z:mpath ids='MPATH_458'>normal</z:mpath> mice </plain></SENT>
<SENT sid="4" pm="."><plain>Twice daily injection of (pGlu<z:chebi fb="0" ids="32668">-Gln</z:chebi>)-CCK-8 alone and in combination with exendin-4 or GIP[mPEG] in high fat-fed mice significantly decreased accumulated food intake (p &lt; 0.05-p &lt; 0.01), body <z:mp ids='MP_0005456'>weight gain</z:mp> (p &lt; 0.05-p &lt; 0.01) and improved (p &lt; 0.05) insulin sensitivity in high fat-fed mice </plain></SENT>
<SENT sid="5" pm="."><plain>However, there was no evidence for superior effects compared to (pGlu<z:chebi fb="0" ids="32668">-Gln</z:chebi>)-CCK-8 alone </plain></SENT>
<SENT sid="6" pm="."><plain>Combined treatment of (pGlu<z:chebi fb="0" ids="32668">-Gln</z:chebi>)-CCK-8 and exendin-4 resulted in significantly (p &lt; 0.05) lowered circulating <z:chebi fb="105" ids="17234">glucose</z:chebi> levels and improved (p &lt; 0.05) intraperitoneal <z:chebi fb="105" ids="17234">glucose</z:chebi> tolerance </plain></SENT>
<SENT sid="7" pm="."><plain>These effects were superior to either treatment regime alone but not associated with altered insulin concentrations </plain></SENT>
<SENT sid="8" pm="."><plain>A single injection of (pGlu<z:chebi fb="0" ids="32668">-Gln</z:chebi>)-CCK-8, or combined with exendin-4, significantly (p &lt; 0.05) lowered blood <z:chebi fb="105" ids="17234">glucose</z:chebi> levels 24â€‰h post injection in untreated high fat-fed mice </plain></SENT>
<SENT sid="9" pm="."><plain>CONCLUSION: This study highlights the potential of (pGlu<z:chebi fb="0" ids="32668">-Gln</z:chebi>)-CCK-8 alone and in combination with incretin hormones for the treatment of type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
</text></document>